Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies

Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Passamonti, Francesco, Maffioli, Margherita, Caramazza, Domenica, Cazzola, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Research Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248205/
https://www.ncbi.nlm.nih.gov/pubmed/21646683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248205/
https://www.ncbi.nlm.nih.gov/pubmed/21646683

Ejemplares similares